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Abstract
Introduction: Among the various drug induced dermatological entities toxic epidermal necrolysis
and Stevens-Johnson’s syndrome occupy a primary place in terms of mortality. Prompt recognition of
these conditions, immediate drug withdrawal and institution of appropriate treatment plays a vital
role in reducing mortality. Drugs are by far the most common cause of toxic epidermal necrolysis, in
which large sheets of skin are lost from the body surface making redundant the barrier function of the
skin, with its resultant complications. The use of systemic corticosteroids in the treatment of toxic
epidermal necrolysis has always been controversial, some consider corticosteroids life-saving while
others believe that they increase mortality.
Case presentation: We describe two cases of drug-induced toxic epidermal necrolysis, a male and
a female, both caucasoids of Pakistani origin, one treated without any steroids and the other with
them, who made complete recovery without any major complications or sequelae.
Conclusion: The administration of systemic corticosteriods did not cause any major changes in
outcome in our cases.
Introduction
Toxic epidermal necrolysis also known as Lyell’s syndrome
is a rare but potentially life threatening condition. It is
primarily a cutaneous reaction to various precipitating
agents, characterized by wide spread erythema and
detachment of the epidermis from the dermis. Toxic
epidermal necrolysis occurs sporadically, more commonly
in adults, with a mean age of 46.8 years. There is no sexual
or racial predilection. It is fairly rare with an annual
incidence of 1.2 cases per million. An increased incidence
has been observed in HLA-B 12 individuals.
Case presentation
Case report 1
A 60-year-old Pakistani male of Caucasoid origin was
admitted to the dermatology unit with the following
history. He had been operated for cataract 05 days ago.
Post-operatively Co-trimoxazole tablets were given. Forty
eight hours after taking the tablets the patient developed a
severe burning sensation all over the body. This was
followed by peeling of sheets of skin over the back,
buttocks, thighs and neck. He had had a similar reaction to
tetracyclines 12 years ago.
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Initial examination revealed an asthenic, sick looking man
with a B.P. of 130/90 mmHg, temperature 99 degree
Fahrenheit and pulse 110/min. Hydration was poor. He
was in obvious distress but conscious and oriented. On
dermatological examination 40% of body surface area
showed peeling of skin in sheets of more than 3 cm leaving
behind superficial erosions. The back, buttocks, thighs and
anterior aspect of the neck were primarily involved
(Figure 1). Skin tenderness and Nickolsky’s sign were
positive. The mucosae were not involved.
At the time of admission the bio-chemical profile was
urea 9 mmol/lit, creatinine 274 umol/lit, potassium
3.6 mmol/lit, and sodium 137 mmol/lit. The serum
total proteins were 4.9 mg/dl with an albumin level of
3.4 mg/dl and an albumin/globulin ratio of 1.5/1. The
blood counts, urinalysis, electrocardiogram and chest
roentogram were unremarkable. Skin biopsy showed a
sub-epidermal split with necrosis of the epidermis and
eosinophilic infiltration.
On the basis of body surface area involved a fluid
requirement of 4 lit/24 hours was deduced, half of
which was administered as Ringer’s lactate and the other
half as glucose saline. He was also put on intravenous
Ceftriaxone 1 gm twice daily. The urinary out-put
improved and temperature returned to normal. Blood
chemistry repeated on the 3rd day revealed no abnorm-
ality. The very next day the patient developed multiple
purpuric and ecchymotic spots over both thighs. Urgent
investigations revealed raised fibrinogen degradation
products levels in both urine and blood; however the
serum fibrinogen, platelets and bleeding profile were
normal. A diagnosis of compensated disseminated
intravascular coagulation was made and fresh frozen
plasma transfused. Over the next couple of days the skin
lesions subsided and fibrinogen degradation products
levels returned to normal. Subsequently the patient made
an uneventful recovery and all the lesions healed without
scarring.
Case report 2
A 45-year-old Pakistani female of Caucasoid origin was
admitted to the dermatology ward with extensive peeling
of skin over the back and buttocks. She had taken a
quinolone (moxifloxacin) for fever 05 days ago which was
followed by a morbilliform eruption and widespread
peeling of skin. She was a known diabetic for the past
10 years on insulin injections. On examination she was
conscious but distressed, dehydrated and febrile with a
temperature of 101 degree Fahrenheit, B.P. 130/90, pulse
98/min. She had skin peeling involving about 60% of the
body surface area including the back, buttocks, face, neck
and limbs (Figures 2-4). Oral and conjunctival mucosae
were severely involved (Figures 5 and 6) and Nicholsky’s
sign and skin tenderness were positive. Biochemical
profile revealed raised serum urea 10.7 mmol/lit, crea-
tinine 75 umol/lit, sodium 137 mmol/lit, potassium
3.8 mmol/lit, her ALT was also raised 87 IU but serum
bilirubin and alkaline phosphatase were within normal
limits. The blood counts, urinalysis, X-rays chest and
electrocardiogram revealed no abnormality. Skin biopsy
showed sub-epidermal clefting with a mixed infiltrate of
polymorphs. The patient was treated with intravenous
dexamethasone 3mg 8 hourly and intravenous ceftriaxone
1 gm twice daily, intravenous insulin on a sliding scale
along with topical antiseptic dressings and fluid and
electrolyte replacement therapy. The steroids were gradu-
ally tapered off and the patient exhibited an uneventful
Figure 1. Peeling of sheets of skin and erosions over the
buttocks (Case no. 1). Figure 2. Peeled skin over the back and buttocks (Case no 2).
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recovery over the next 2 weeks; all the skin lesions healed
without scarring and there were no sequelae except for a
corneal opacity in the right eye.
Discussion
Toxic epidermal necrolysis also known as Lyell’s syndrome
was first described by Lyell in 1956. The word toxic alludes
to the constitutional symptoms while necrolysis refers to
the necrosis and detachment of the full thickness of the
epidermis [1].
Drugs are the most common cause accounting for about
65%-80% of the cases. The most common offending
agents are sulfonamides, NSAIDs, butazones and hydran-
toins [2]. The risks related to different drugs are different
even for closely chemically related products. Multiple
precipitating causes may co-exist [3]. The earlier a
causative agent is withdrawn the better is the prognosis.
Patients on drugs with longer half-lives have an increased
chance of dying [4]. An increased incidence of toxic
epidermal necrolysis has been observed in patients with
brain tumors, systemic lupus erythmatosus, acquired
immune deficiency syndrome and high dose steroid
therapy [5]. Other precipitating causes include viruses,
bacteria, fungi, immunization, neoplasms, graft versus
host disease, radiotherapy, beverages fumigants and
idiopathic.
An immune mechanism is implicated in the pathogenesis
but its nature is still unclear. It is primarily directed at drug
modified epidermal cells [5]. Different immuno-inflam-
matory pathways with early participation of activated CD8
T-lymphocytes are involved. Blister fluid contains signifi-
cantly higher levels of soluble interleukin-2 receptors
(sIL-2R) probably related to a local down-regulation of an
immune mediated cytotoxic reaction [6].
Figure 3. Involvement of the face (Case no. 2).
Figure 4. Rash and erosion over the lower limb (Case no. 2).
Figure 5. Involvement of the oral mucosa (Case no. 2).
Figure 6. Involvement of the conjunctival mucosa (Case no. 2).
Page 3 of 5
(page number not for citation purposes)
Cases Journal 2009, 2:7765 http://casesjournal.com/casesjournal/article/view/7765
Microscopically, there is sub-epidermal bullae formation,
with eosinophilic epidermal necrosis. The dermal vessels
show endothelial swelling without any vasculitis or
necrosis. Ultra-structurally there is damage to the basal
and lower spinous levels of the epidermis and cleft
formation at the lamina densa. Immuno-florescence is
always negative [7].
The interval between the intake of a drug and the onset of
symptoms generally ranges from a few hours to 22 days
with a maximum of 38 days recorded in case of anti-
tuberculosis drugs [8].
There is a prodormal phase in which there is burning
sensation all over the skin and conjunctivae, along with
skin tenderness, fever, malaise and arthralgias. This is
followed by the eruptive phase in which a morbilliform
rash erupts in the axillae and groins and rapidly becomes
confluent into a pale, livid, confluent erythema, sparing
only the hairy areas. In the acme or peak phase, vesicles
and flaccid bullae appear which rupture quickly to leave
denuded areas mainly at pressure points. Fluid and
protein loss occurs as in 2nd degree burns. Nickolsky’s
sign is positive in erythematous skin.
As a rule oral, genital and anal mucous membranes are
severely involved. Nail shedding and hair loss may occur.
Mucous membrane involvement occurs in 85%-95%
cases and precedes the skin involvement in one third of
cases [5].
The following diagnostic criteria must be fulfilled for a
case to be labeled as toxic epidermal necrolysis.
1. Bullae or erosions involving more than 20% of body
surface area or three different anatomical sites.
2. Skin peeling in sheets of more than 3 cm.
3. Involvement of non-exposed skin.
4. Mucous membranes frequently involved.
5. Skin tenderness within 48 hours of rash.
6. Biopsy confirmation within 48 hours.
7. Fever.
8. Bullae arising on an erythematous background.
9. Exclusion of Staphylococcal scalded skin syndrome.
Investigations usually show leukocytosis, albuminuria,
water and electrolyte imbalance and raised transaminases.
Leukopenia and thrombocytopenia occur in some cases.
Lymphopenia with selective depression of CD4 T-helper
cells may occur.
Complications include hypovolemic shock, pulmonary
edema, acute tubular necrosis, membranous glomerulo-
nephritis, gastrointestinal hemorrhage, bronchopneumo-
nia and disseminated intravascular coagulation. Cicatricial
alopecia, anonychia, ectropion, entropion and corneal
opacities can also occur.
Recovery is slow over a period of 14-28 days and relapses
are frequent. There is a tendency for scarring in all but the
mildest of cases. Mortality is 25%-50% and rises with age,
being more than 50% above 60 years of age. Half the
deaths occur due to secondary infection. Pulmonary
edema, pulmonary embolism and gastrointestinal hemor-
rhage are other important causes of mortality. Sequelae
occur in 40% of cases and are mainly ocular such as
ectropion, entropion, synechieae, pannus formation and
sicca syndrome. Reticulate skin pigmentation may occur
over the affected areas [5].
Treatment is mainly supportive with removal of the
precipitating agent, good nursing care preferably on a
ripple bed, care of the eyes and mouth to prevent scarring
and infection and maintenance of fluid and electrolyte
balance. Intravenous fluids given during the first 24 hours
should include 1 ml/kg/% of body surface area involved of
macromolecules (albumin), plus 0.7 ml/kg/% surface area
of isotonic saline. In addition 1500 ml of fluids should
be given through the naso-gastric tube during the first
24 hours. Intravenous fluids should be supplemented with
potassium.
The patient should be put on a high protein diet 2-3 gms/kg
daily. At least 2000 cal should be given during the first
24 hours increasing by 500 cal/day upto a maximum of
4000 cal/day. Naso-gastric feeding is preferable in
severely ill patients. Temperature should be maintained
at 30-32 degree Celsius. Topical Chlorhexidine or Silver
nitrate may be used to wash denuded areas. Silver
sulfadiazine should be avoided due to the implications
of sulfonamides in toxic epidermal necrolysis [9].
Anti-coagulation with Heparin for the duration of
the hospital stay has been advocated [5]. Some authorities
advocate immediate covering of denuded areas
with biologic dressings like porcine xenografts, cryopre-
served allografts or amnion and collagen based skin
substitutes [10].
The role of steroids is controversial. Their efficacy has
never been conclusively demonstrated. A number of cases
of toxic epidermal necrolysis have occurred in patients
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who were already on high-dose steroids [11]. Retro-
spective studies indicate a higher death rate in patients
on steroids and that steroids do not prevent the occurrence
or extension of epidermal necrolysis [12]. Another study
has reported 66% survival rate in patients managed
without steroids as compared to a 33% survival in patients
on steroid therapy. The former group had a decreased
incidence of gastrointestinal ulceration, candidal infection
and better recovery rate from septic complications [13].
Early infusion of high-dose Intravenous Immunoglo-
bulins (IVIG) causes a rapid cessation of skin and mucosal
detachment in a majority of patients [7]. According to a
study patients treated with IVIG have 83% less chance of
dying than those not treated with it [14]. Contrarily
another study has shown no beneficial effect of IVIG
therapy [15].
Abbreviations
HLA, human leukocyte antigen; IVIG, intravenous immu-
noglobulins; NSAIDs, non steroidal anti inflammatory
drugs.
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